Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Genetic influences on aspirin response in patients undergoing percutaneous coronary intervention.

Friede KA, Voora D.

Cardiovasc Res. 2019 Aug 1;115(10):1452-1453. doi: 10.1093/cvr/cvz110. No abstract available.

PMID:
31049556
2.

Pilot study of myocardial ischemia-induced metabolomic changes in emergency department patients undergoing stress testing.

Limkakeng AT Jr, Henao R, Voora D, O'Connell T, Griffin M, Tsalik EL, Shah S, Woods CW, Ginsburg GS.

PLoS One. 2019 Feb 1;14(2):e0211762. doi: 10.1371/journal.pone.0211762. eCollection 2019.

3.

Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.

Peyser B, Perry EP, Singh K, Gill RD, Mehan MR, Haga SB, Musty MD, Milazzo NA, Savard D, Li YJ, Trujilio G, Voora D.

Circ Genom Precis Med. 2018 Sep;11(9):e002228. doi: 10.1161/CIRCGEN.118.002228.

PMID:
30354330
4.

Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study.

Parker WAE, Eriksson N, Becker RC, Voora D, Åkerblom A, Himmelmann A, James SK, Wallentin L, Storey RF; PLATO Investigators.

Platelets. 2019;30(5):579-588. doi: 10.1080/09537104.2018.1478404. Epub 2018 May 31.

PMID:
29851527
5.

Future directions in pharmacogenomics discovery in cardiovascular disease.

Friede KA, Voora D.

Pharmacogenomics. 2018 Apr;19(5):375-377. doi: 10.2217/pgs-2018-0002. Epub 2018 Mar 23. No abstract available.

6.

Peripheral blood gene expression signatures which reflect smoking and aspirin exposure are associated with cardiovascular events.

Wingrove JA, Fitch K, Rhees B, Rosenberg S, Voora D.

BMC Med Genomics. 2018 Jan 12;11(1):1. doi: 10.1186/s12920-017-0318-6.

7.

An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System.

Lucas JE, Bazemore TC, Alo C, Monahan PB, Voora D.

PLoS One. 2017 Nov 20;12(11):e0187809. doi: 10.1371/journal.pone.0187809. eCollection 2017.

8.

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA; IGNITE Network.

JACC Cardiovasc Interv. 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1.

9.

The need for sex-specific precision biomarkers for antiplatelet therapies.

Friede K, Voora D.

Future Cardiol. 2017 Aug 23. doi: 10.2217/fca-2017-0043. [Epub ahead of print] No abstract available.

PMID:
28832186
10.

The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association.

Musunuru K, Ingelsson E, Fornage M, Liu P, Murphy AM, Newby LK, Newton-Cheh C, Perez MV, Voora D, Woo D; American Heart Association Committee on Molecular Determinants of Cardiovascular Health of the Council on Functional Genomics and Translational Biology and Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; and Stroke Council.

Circ Cardiovasc Genet. 2017 Aug;10(4). pii: e000037. doi: 10.1161/HCG.0000000000000037. Review.

PMID:
28760750
11.

Transcription Factor RUNX1 Regulates Platelet PCTP (Phosphatidylcholine Transfer Protein): Implications for Cardiovascular Events: Differential Effects of RUNX1 Variants.

Mao G, Songdej N, Voora D, Goldfinger LE, Del Carpio-Cano FE, Myers RA, Rao AK.

Circulation. 2017 Sep 5;136(10):927-939. doi: 10.1161/CIRCULATIONAHA.116.023711. Epub 2017 Jul 4.

12.

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.

Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, Lee CR, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA.

Clin Transl Sci. 2017 May;10(3):143-146. doi: 10.1111/cts.12456. Epub 2017 Mar 14. Review. No abstract available.

13.

Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.

Haga SB, Moaddeb J, Mills R, Voora D.

Pharmacogenomics. 2017 Mar;18(4):327-335. doi: 10.2217/pgs-2016-0175. Epub 2017 Feb 22.

14.

An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.

Voora D, Coles A, Lee KL, Hoffmann U, Wingrove JA, Rhees B, Huang L, Daniels SE, Monane M, Rosenberg S, Shah SH, Kraus WE, Ginsburg GS, Douglas PS.

Am Heart J. 2017 Feb;184:133-140. doi: 10.1016/j.ahj.2016.11.004. Epub 2016 Nov 15.

15.

Circulating extracellular vesicles containing miRNAs may have utility as early biomarkers for cardiac injury.

Doran B, Voora D.

Ann Transl Med. 2016 Oct;4(Suppl 1):S60. No abstract available.

16.

Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease.

Friede K, Li J, Voora D.

Clin Chem. 2017 Jan;63(1):177-185. doi: 10.1373/clinchem.2016.255232. Epub 2016 Nov 18. Review.

17.

Rationale and design of the SLCO1B1 genotype guided statin therapy trial.

Singh K, Peyser B, Trujillo G, Milazzo N, Savard D, Haga SB, Musty M, Voora D.

Pharmacogenomics. 2016 Nov;17(17):1873-1880. doi: 10.2217/pgs-2016-0065. Epub 2016 Nov 3. No abstract available.

PMID:
27807988
18.

Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer.

Voora D, Rao AK, Jalagadugula GS, Myers R, Harris E, Ortel TL, Ginsburg GS.

EBioMedicine. 2016 Sep;11:157-164. doi: 10.1016/j.ebiom.2016.08.021. Epub 2016 Aug 14.

19.

Pharmacometabolomics Meets Genetics: A "Natural" Clinical Trial of Statin Effects.

Voora D, Shah SH.

J Am Coll Cardiol. 2016 Mar 15;67(10):1211-1213. doi: 10.1016/j.jacc.2016.01.022. No abstract available.

20.

Genome-wide association study on progression of carotid artery intima media thickness over 10 years in a Chinese cohort.

Xie G, Myint PK, Voora D, Laskowitz DT, Shi P, Ren F, Wang H, Yang Y, Huo Y, Gao W, Wu Y.

Atherosclerosis. 2015 Nov;243(1):30-7. doi: 10.1016/j.atherosclerosis.2015.08.034. Epub 2015 Sep 5.

PMID:
26343869
21.

Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction.

Rose JJ, Voora D, Cyr DD, Lucas JE, Zaas AK, Woods CW, Newby LK, Kraus WE, Ginsburg GS.

PLoS One. 2015 Jul 20;10(7):e0132259. doi: 10.1371/journal.pone.0132259. eCollection 2015.

22.

Gene Expression Signatures and the Spectrum of Coronary Artery Disease.

Friede KA, Ginsburg GS, Voora D.

J Cardiovasc Transl Res. 2015 Aug;8(6):339-52. doi: 10.1007/s12265-015-9640-6. Epub 2015 Jun 19. Review.

PMID:
26089288
23.

Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.

Varenhorst C, Eriksson N, Johansson Å, Barratt BJ, Hagström E, Åkerblom A, Syvänen AC, Becker RC, James SK, Katus HA, Husted S, Steg PG, Siegbahn A, Voora D, Teng R, Storey RF, Wallentin L; PLATO Investigators.

Eur Heart J. 2015 Aug 1;36(29):1901-12. doi: 10.1093/eurheartj/ehv116. Epub 2015 May 2.

PMID:
25935875
24.

SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.

Li JH, Suchindran S, Shah SH, Kraus WE, Ginsburg GS, Voora D.

Pharmacogenomics. 2015;16(5):449-58. doi: 10.2217/pgs.15.2.

25.

Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics.

Beitelshees AL, Voora D, Lewis JP.

Pharmgenomics Pers Med. 2015 Feb 9;8:43-61. doi: 10.2147/PGPM.S52900. eCollection 2015. Review.

26.

Module-based association analysis for omics data with network structure.

Wang Z, Maity A, Hsiao CK, Voora D, Kaddurah-Daouk R, Tzeng JY.

PLoS One. 2015 Mar 30;10(3):e0122309. doi: 10.1371/journal.pone.0122309. eCollection 2015.

27.

Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients.

Li JH, Joy SV, Haga SB, Orlando LA, Kraus WE, Ginsburg GS, Voora D.

J Pers Med. 2014 Mar 27;4(2):147-62. doi: 10.3390/jpm4020147.

28.

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M.

Clin Pharmacol Ther. 2014 Oct;96(4):423-8. doi: 10.1038/clpt.2014.125. Epub 2014 Jun 11.

29.

Phenotype standardization for statin-induced myotoxicity.

Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, Carr DF, Bloch KM, Fahy J, Hanson A, Yue QY, Wadelius M, Maitland-van Der Zee AH, Voora D, Psaty BM, Palmer CN, Pirmohamed M.

Clin Pharmacol Ther. 2014 Oct;96(4):470-6. doi: 10.1038/clpt.2014.121. Epub 2014 Jun 4.

30.

Expression quantitative trait locus analysis identifies novel genes for statin myopathy.

Voora D.

Circ Cardiovasc Genet. 2014 Apr;7(2):220-1. doi: 10.1161/CIRCGENETICS.114.000611. No abstract available.

PMID:
24736853
31.

A freeze on tailored antiplatelet therapy?

Voora D, Becker RC.

Circulation. 2014 May 27;129(21):2088-90. doi: 10.1161/CIRCULATIONAHA.114.009930. Epub 2014 Apr 9. No abstract available.

PMID:
24718567
32.

Platelet RNA as a novel biomarker for the response to antiplatelet therapy.

Voora D, Ginsburg GS, Akerblom A.

Future Cardiol. 2014 Jan;10(1):9-12. doi: 10.2217/fca.13.90. No abstract available.

PMID:
24344654
33.

Preoperative CYP2D6 metabolism-dependent β-blocker use and mortality after coronary artery bypass grafting surgery.

Kertai MD, Esper SA, Akushevich I, Voora D, Ginsburg GS, Stafford-Smith M, Grichnik K, Newman MF, Fontes ML, Smith P, Podgoreanu MV, Mathew JP; Cardiothoracic Anesthesia Research Endeavors (CARE) Group.

J Thorac Cardiovasc Surg. 2014 Apr;147(4):1368-1375.e3. doi: 10.1016/j.jtcvs.2013.09.067. Epub 2013 Nov 21.

34.

Delivering pharmacogenetic testing in a primary care setting.

Mills R, Voora D, Peyser B, Haga SB.

Pharmgenomics Pers Med. 2013 Sep 18;6:105-12. doi: 10.2147/PGPM.S50598. eCollection 2013.

35.

A host-based RT-PCR gene expression signature to identify acute respiratory viral infection.

Zaas AK, Burke T, Chen M, McClain M, Nicholson B, Veldman T, Tsalik EL, Fowler V, Rivers EP, Otero R, Kingsmore SF, Voora D, Lucas J, Hero AO, Carin L, Woods CW, Ginsburg GS.

Sci Transl Med. 2013 Sep 18;5(203):203ra126. doi: 10.1126/scitranslmed.3006280.

36.

Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events.

Voora D, Cyr D, Lucas J, Chi JT, Dungan J, McCaffrey TA, Katz R, Newby LK, Kraus WE, Becker RC, Ortel TL, Ginsburg GS.

J Am Coll Cardiol. 2013 Oct 1;62(14):1267-1276. doi: 10.1016/j.jacc.2013.05.073. Epub 2013 Jul 3.

37.

A transcriptomics-informed genetic association study identifies RHOA in simvastatin-induced low-density lipoprotein cholesterol lowering.

Voora D.

Circ Cardiovasc Genet. 2013 Feb;6(1):137-8. doi: 10.1161/CIRCGENETICS.111.000070. No abstract available.

PMID:
23424259
38.

Building the evidentiary framework for pharmacogenetic testing: is it time to move beyond randomized controlled trials?

Voora D.

Per Med. 2013 Jan;10(1):1-3. doi: 10.2217/pme.12.105. No abstract available.

39.

Clinical application of cardiovascular pharmacogenetics.

Voora D, Ginsburg GS.

J Am Coll Cardiol. 2012 Jul 3;60(1):9-20. doi: 10.1016/j.jacc.2012.01.067. Review.

40.

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M; Clinical Pharmacogenomics Implementation Consortium (CPIC).

Clin Pharmacol Ther. 2012 Jul;92(1):112-7. doi: 10.1038/clpt.2012.57. Epub 2012 May 23.

41.

Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.

Voora D, Ortel TL, Lucas JE, Chi JT, Becker RC, Ginsburg GS.

J Thromb Thrombolysis. 2012 Apr;33(3):246-57. doi: 10.1007/s11239-012-0683-0.

42.

A hub for bench-to-bedside pharmacogenomic-based research.

Voora D, Ginsburg GS.

Pharmacogenomics. 2011 Aug;12(8):1095-8. doi: 10.2217/pgs.11.62.

PMID:
21843063
43.

The pharmacogenetics of antiplatelet agents: towards personalized therapy?

Ahmad T, Voora D, Becker RC.

Nat Rev Cardiol. 2011 Aug 9;8(10):560-71. doi: 10.1038/nrcardio.2011.111. Review.

PMID:
21826075
44.

Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use.

Voora D, Horton J, Shah SH, Shaw LK, Newby LK.

Am Heart J. 2011 Jul;162(1):166-72.e1. doi: 10.1016/j.ahj.2011.03.026.

PMID:
21742104
45.

The long and winding road to warfarin pharmacogenetic testing.

Ginsburg GS, Voora D.

J Am Coll Cardiol. 2010 Jun 22;55(25):2813-5. doi: 10.1016/j.jacc.2010.04.006. No abstract available.

46.

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, Cavallari LH, Ridker PM, Grice GR, Miller RD, Gage BF.

Clin Pharmacol Ther. 2010 Apr;87(4):445-51. doi: 10.1038/clpt.2009.291. Epub 2010 Mar 3.

47.

Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation.

Wallace TW, Atwater BD, Daubert JP, Voora D, Crowley AL, Bahnson TD, Hranitzky PM.

J Cardiovasc Electrophysiol. 2010 Aug 1;21(8):849-52. doi: 10.1111/j.1540-8167.2010.01729.x. Epub 2010 Feb 11.

PMID:
20158561
48.

Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.

Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR, Messer C, Salisbury BA, Ginsburg GS.

Circ Cardiovasc Genet. 2008 Dec;1(2):100-6. doi: 10.1161/CIRCGENETICS.108.795013. Epub 2008 Dec 9.

49.

The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS.

J Am Coll Cardiol. 2009 Oct 20;54(17):1609-16. doi: 10.1016/j.jacc.2009.04.053.

50.

Evaluation of the PharmGKB knowledge base as a resource for efficiently assessing the clinical validity and utility of pharmacogenetic assays.

Kawamoto K, Orlando LA, Voora D, Lobach DF, Joy S, Cho A, Ginsburg GS.

AMIA Annu Symp Proc. 2009 Nov 14;2009:307-11.

Supplemental Content

Support Center